• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Elevation Oncology Inc.

    4/16/25 9:16:44 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Elevation Oncology, Inc.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    28623U101

    (CUSIP Number)


    Braden M Leonard
    65 E Cedar - Suite2,
    Zionsville, IN, 46077
    317-344-2447

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/16/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    28623U101


    1 Name of reporting person

    BML Investment Partners, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    5,890,934.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    5,890,934.00
    11Aggregate amount beneficially owned by each reporting person

    5,890,934.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common stock, par value $0.0001 per share
    (b)Name of Issuer:

    Elevation Oncology, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    101 Federal Street, Boston, UNITED STATES , 02110.
    Item 2.Identity and Background
    (a)
    Braden M. Leonard Mr. Leonard's business address is 65 E Cedar Suite 2, Zionsville, IN 46077. Mr. Leonard's principal business is to serve as managing member of BML Capital Management, LLC.
    (b)
    65 E Cedar - Suite 2, Zionsville IN 46077
    (c)
    See above.
    (d)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Braden M. Leonard is a citizen of the United States of America.
    Item 3.Source and Amount of Funds or Other Consideration
     
    BML Investment Partners, L.P. holds 5,890,934 shares of Common Stock which were acquired using $1,711,725 of working capital.
    Item 4.Purpose of Transaction
     
    The Reporting Persons purchased the Common Stock reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including but not limited to its businesses, results of operations, and prospects. All of the shares of Common Stock reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. Except as set forth herein, none of the Reporting Persons has any plans or proposals that related to or would result in any of the transactions described in Item 4 of Schedule 13D. On April 16, 2025, the Reporting Person sent a letter to the Issuer's Board expressing its belief that an orderly winddown, liquidation, and capital return is in the best interets of the shareholders of the Issuer. The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors.
    Item 5.Interest in Securities of the Issuer
    (a)
    BML Investment Partners, L.P. beneficially owned 5,890,934 shares of the Issuer's Common Stock, or 9.9% based on 59,215,795 of shares outstanding as set forth on the cover of the Issuer's Form 10-K filed on March 6, 2025.
    (b)
    See iten 5(a) above.
    (c)
    None of the Reporting Persons has effected any transactions in the Issuer's Common Stock during the 60 days preceding the date of this Schedule 13D.
    (d)
    Braden M Leonard is the Managing Member of BML Capital Management, LLC, which is the General Partner to BML Investment Partners, L.P.
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    1 - Letter dated April 16, 2025 from BML Capital Management, LLC to the Board of Directors of the Issuer.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BML Investment Partners, L.P.
     
    Signature:Braden M Leonard
    Name/Title:Braden M Leonard - Managing Member of BML Capital Management, LLC
    Date:04/16/2025
    Get the next $ELEV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevation Oncology downgraded by Stephens with a new price target

      Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

      3/24/25 8:34:27 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

      3/21/25 8:03:34 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Citizens JMP

      Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

      3/21/25 8:03:24 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Financials

    Live finance-specific insights

    See more
    • Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

      -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

      8/6/24 7:10:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

      -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

      8/6/24 7:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

      Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

      7/28/22 8:45:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

      BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

      3/4/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

      BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

      1/22/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

      NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

      7/13/23 8:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

      5/15/25 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

      4/25/25 1:00:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- -- On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON, March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the Amer

      3/25/25 4:30:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Furlong Tammy converted options into 2,643 shares and covered exercise/tax liability with 784 shares, increasing direct ownership by 23% to 10,075 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:15:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 6,250 shares and covered exercise/tax liability with 2,303 shares, increasing direct ownership by 3% to 137,152 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:10:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 12,562 shares and covered exercise/tax liability with 4,628 shares, increasing direct ownership by 6% to 133,205 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      3/18/25 4:15:13 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:27:14 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:15:23 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elevation Oncology, Inc. (0001783032) (Filer)

      5/15/25 7:45:11 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:50:19 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:05:59 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 6:45:37 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care